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Abstract
Background: Epidermal growth factor receptor (EGFR) signaling plays an important role in non-small cell lung
cancer (NSCLC) and therapeutics targeted against EGFR have been effective in treating a subset of patients bearing
somatic EFGR mutations. However, the cancer eventually progresses during treatment with EGFR inhibitors, even in
the patients who respond to these drugs initially. Recent studies have identified that the acquisition of resistance
in approximately 50% of cases is due to generation of a secondary mutation (T790M) in the EGFR kinase domain.
In about 20% of the cases, resistance is associated with the amplification of MET kinase. In the remaining 30-40%
of the cases, the mechanism underpinning the therapeutic resistance is unknown.
Methods: An erlotinib resistant subline (H1650-ER1) was generated upon continuous exposure of NSCLC cell line
NCI-H1650 to erlotinib. Cancer stem cell like traits including expression of stem cell markers, enhanced ability to
self-renew and differentiate, and increased tumorigenicity in vitro were assessed in erlotinib resistant H1650-ER1
cells.
Results: The erlotinib resistant subline contained a population of cells with properties similar to cancer stem cells.
These cells were found to be less sensitive towards erlotinib treatment as measured by cell proliferation and
generation of tumor spheres in the presence of erlotinib.
Conclusions: Our findings suggest that in cases of NSCLC accompanied by mutant EGFR, treatment targeting
inhibition of EGFR kinase activity in differentiated cancer cells may generate a population of cancer cells with stem
cell properties.
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Background
Recent years have seen the emergence of therapeutics
directed against specific signaling pathways critical for
the onset and progression of cancer. Protein tyrosine
kinases (PTKs), by the virtue of their regulation of cellu-
lar functions that contribute to cancer, including cell
proliferation, survival, apoptosis, migration, and DNA
damage repair, have emerged as new anticancer targets.
Rational targeting of PTK activity to control these sig-
naling pathways, and thus correct aberrant cellular
b e h a v i o r si nc a n c e r ,h a sb e e ns u c c e s s f u li ni m p r o v i n g
outcomes of many types of cancer [1]. Moreover, the
specificity of these targeted drugs results in fewer and
less severe side effects compared to conventional cancer
treatments which are non specific in their actions. Of
the approximately 20 classes of PTKs, the epidermal
growth factor receptor (EGFR) family, whose members
include HER1 (EGFR), HER2/neu (ErbB2), HER3
(ErbB3), and Her4 (ErbB4) [2], has been the most widely
studied. While the EGFR signaling cascade is essential
for homeostasis, dysregulation of EGFR kinase activity
has been implicated in the oncogenic transformation of
cells [3,4]. EGFR overexpression, gene amplification,
mutations, and increased kinase activity have been
observed in many solid cancers of epithelial origin
including breast, lung, head and neck, ovarian, bladder,
and pancreatic cancers [2,5].
Specifically, frequent abnormal amplification or activa-
tion of EGFR has been observed in non-small cell lung
cancer (NSCLC). Two small molecule EGFR tyrosine
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any medium, provided the original work is properly cited.kinase inhibitors (EGFR-TKI), gefitinib (Iressa, AstraZe-
neca International) and erlotinib (Tarveca, OSI Pharma-
ceuticals) have been evaluated in patients with NSCLC
[6,7]. These ATP competitive, reversible EGFR-TKIs
have been effective only in a small subset of NSCLC
patients bearing somatic mutations (deletions in exon
19 and the L858R mutation) in the kinase domain of
EGFR [8]. Nevertheless, patients initially responding to
TKI therapy invariably develop resistance to these drugs,
thereby limiting progression-free survival to approxi-
mately 9-13 months with a median survival of 2 years
[9]. In the past several years, studies underpinned the
molecular mechanisms responsible for drug resistance
including acquisition of secondary mutation in EGFR
kinase domain (threonine to methionine mutation,
T790M) and/or c-MET amplification [10-13]. However,
t h e s ec o n s t i t u t eo n l y~ 5 0 - 7 0 %o fE G F R - T K Ir e s i s t a n t
cases, indicating mechanisms leading to resistance in the
remaining cases are yet to be unraveled. Recent endea-
vors have identified that in addition to increased recep-
tor internalization or altered EGFR trafficking [14],
epithelial to mesenchymal transition (EMT) can be
related with acquisition of resistance towards EGFR
TKIs [15-18].
EMT, characterized by the loss of cell-cell junctions,
repression of E-cadherin expression and gain of
mesenchymal markers significantly contributes to cancer
invasion and metastasis. Recent evidence indicates EMT
induction in tumor cells can also lead to emergence
and/or enrichment of cancer stem cells (CSCs) [19].
CSCs, also known as tumor initiating cells or cancer
stem like cells, refer to a minor subpopulation of cancer
cells with properties similar to somatic stem cells
including self-renewal and multi-lineage differentiation.
Initially identified in acute myeloid leukemia, CSCs have
later been found in various cancers including breast,
lung, brain, pancreatic, and prostate cancer [20-27]. By
the virtue of altered cell cycle kinetics, increased DNA
repair response, increased expression of antiapoptotic
regulators as well as transporter proteins, CSCs are able
to survive radiation or chemotherapeutic insults [28].
Thus, these cells are more refractory to cytotoxic agents
compared to the differentiated cancer cells which consti-
tute the bulk of the tumor. In fact it is believed that
CSCs contribute significantly to tumor relapse following
chemo or radiotherapy.
Based on these observations, we speculated that CSC
selection during prolonged exposure to EGFR TKIs may
play a role in eventual progression of cancer after a period
of successful response. Recent evidence shows existence of
a population of cells expressing cancer stem cell markers
CD44
high/CD24
low in erlotinib resistant non small cell
lung cancer (NSCLC) cell lines [15]. However, to the best
our knowledge these cells were not characterized in terms
of their potential to self-renew, differentiate or induce
resistance to EGFR-TKI therapy. In this study we gener-
ated an erlotinib resistant subline (H1650-ER1) from erlo-
tinib sensitive lung cancer cell line NCI-H1650.
Enrichment of cells with CSC markers and phenotypes in
the resistant subline was confirmed by several techniques:
(a) expression profiling of cell surface markers, (b) side
population (SP) analysis (identification of a population of
cells, called SP, characterized by high efflux of DNA-bind-
ing dye, Hoechst 33342 or DyeCycle Violet (DCV) dye by
ABCG2, an ATP binding cassette transporter [29,30]) and
(c) culture of cells in suspension in serum free medium to
promote generation of tumor spheroids.
Our studies demonstrate that the erlotinib resistant
subline was composed of an increased population of can-
cer stem cell-like cells and exhibited enhanced colony
formation ability in soft agar. SP cells isolated from
H1650-ER1 showed self-renewal as well as differentiation
potential. Furthermore, SP cells were more resistant to
EGFR-TKIs than non-SP cells. These observations indi-
cate that resistance to molecular targeted therapy could
arise from selection and enrichment of cancer stem cell-
like cells, which are intrinsically resistant to erlotinib.
Methods
Cells
Human lung cancer cell line NCI-H1650 (hence forth
referred to as H1650) was obtained from ATCC (Mana-
ssas, VA). The cells were maintained in RPMI-1640 sup-
plemented with 10% FBS and glutamine. During culture,
the medium was changed every other day. The cells
were passaged every 5-6 days using Trypsin-EDTA
(0.25% trypsin, 1 mM EDTA). Generation of the H1650-
ER1 subline has been described previously [31]. Briefly,
starting with an erlotinib (LC labs, Woburn, MA) con-
centration of 2.5 μM ,t h ee x p o s u r ed o s ew a sd o u b l e d
every 15 days until a final concentration of 20 μMw a s
achieved. The cells were maintained in continuous cul-
ture at of 20 μM erlotinib for 30 days. Then the resis-
tance phenotype of the pools was characterized by a cell
proliferation assay. The resistant pool was then used to
establish individual clones. The established clones were
further maintained in culture with 20 μM erlotinib for
another 30 days. Cell viability was then measured fol-
lowing exposure to varying concentrations of erlotinib.
Prior to any experiment, the cells were cultured in med-
ium lacking erlotinib for at least a week.
Human head and neck squamous cell carcinoma cell
line SCC-1 and erlotinib and gefitinib resistant sublines
(SCC-1-Erl-R and SCC-1-Gef-R) were maintained in
DMEM supplemented with 10% FBS, and 1 μg/mL
hydrocortisone.
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H1650 and H1650-ER1 cells were seeded in each well of 6
well plates and allowed to reach confluence. Once conflu-
ent, a wound was inflicted in the monolayer by scraping
with a sterile 200 μL pipette tip. The cell monolayer was
then washed three times with DPBS to remove the cell
debris and incubated with the growth media. Pictures of
the wound were captured at time points t = 0 and t = 12 h
to calculate the wound area. Migration of the cells was cal-
culated fractional closure of the wound area.
Spheroid formation assay
Liquid overlay culture was used to investigate the capacity
of the cells to form spheroids. For the purpose, each well
of 6 well plates was covered with a thin film of 1% agarose
in serum free DMEM/F12 medium. Cell monolayers were
dissociated with trypsin-EDTA into single cells and resus-
pended in DMEM/F12 (Invitrogen, Carlsbad, CA) medium
supplemented with human recombinant epidermal growth
factor (EGF; 10 ng/ml) and basic fibroblast growth factor
receptor (bFGF; 10 ng/ml) and plated in agarose coated 6
well plates. The medium was replaced every 3 days. In
order to assess self renewal through formation of second-
ary spheroids, the spheroids were collected by centrifuga-
tion, dissociated into single cells by treating with trypsin
and passing through 40 μm cell strainer, and then cultured
under conditions described above.
SP analysis
To identify SP cells, cells were stained with DyeCycle
Violet (DCV) stain (Invitrogen, Carlsbad, CA) using
methods modified from Telford et al [30]. Briefly, cells at
ad e n s i t yo f1 0
6 cells/ml were incubated with DCV dye
(10 μM) with or without 50 μM verapamil (Sigma, St.
Louis, MO) at 37°C for 90 min with intermittent shaking.
At the end of the staining, the cells were washed in ice
cold PBS and resuspended in ice cold RPMI-1640 med-
ium. Propidium iodide at the final concentration of 2 μg/
ml was added to the cells to gate viable cells and the cells
were immediately placed in ice. Analysis was carried out
on a BD LSR II flow cytometer or flow sorted on a BD
F A C S A r i a( B DB i o s c i e n c e s ,S a nJ o s e ,C A ) .D C Vd y ew a s
excited by violet diode laser (408 nm) and its fluores-
cence was dual wavelength analyzed (blue 450/40 nm;
red 650 nm LP).
In order to investigate the ability of SP cells to differ-
entiate, sorted SP and non SP cells were cultured in
RPMI 1640 for 10 days. The cells were then stained with
DCV dye and the SP fraction of the two subpopulations
was determined.
Soft-agar assay
To determine the anchorage independent growth poten-
tial, colony formation in soft agar was measured. For
the base layer, 1 mL of 0.5% of agar in RPMI 1640 was
added in each well of 6 well plates. A top layer consist-
ing of 2500 cells suspended in 0.35% agar in RPMI 1640
was plated on top of the base layer. Agar plates were
incubated at 37°C for 2 weeks. Growth medium
(RPMI1640 supplemented with 10% FBS and 2 mM glu-
tamine) was changed every 3 days. After 2 weeks, the
colonies were stained with 0.005% crystal violet and
colonies > 20 μm were counted. Three independent
assays were performed in duplicate.
Cell viability assay
SP and non SP cells sorted from H1650 and H1650-ER1
cells were seeded at a density of 5 × 10
3 cells/well in 96
well plates. After 24 hr, erlotinib at varying concentra-
tions was added and the cells were incubated further for
48 hr. The cells were then washed with PBS and cell
viability was measured using a XTT assay kit (Sigma, St.
Louis, MO).
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was conducted to
examine the mRNA expression of E-cadherin, vimentin,
occludin, fibronectin, OCT3/4, NANOG, SOX-2, ID2
and GAPDH in H1650 and H1650-ER1 cells. The mRNA
expression of OCT3/4, NANOG, BMI1 and STAT3 was
investigated in H1650-ER1 cells, H1650-ER1 spheroids
and adherent cells. Total RNA from the cells were
extracted using RNeasy Mini kit (Qiagen, Valencia, CA)
and cDNA was generated using high capacity cDNA
reverse transcription kit (Applied Biosystems). qRT-PCR
was performed with SYBR Green PCR master mix
(Applied Biosystems, Carlsbad, CA) following manufac-
turer’s instructions. Gene expression in H1650, H1650-
ER1 cells, H1650-ER1 spheroids and adherent cells was
initially normalized against GAPDH to obtain ΔCt values.
Relative fold change in gene expression was then com-
pared between H1650-ER1 and H1650 or H1650-ER1
spheroids, adherent cells and H1650-ER1 cells using ΔCt
method of quantitation. ΔCt values of different cell popu-
lations were used to performstatistical analysis. p-value <
0.05 was considered significantly different. The primers
are listed in Table 1.
Immunofluorescence
H1650 and H1650-ER1 cells were fixed in 4% parafor-
maldehyde for 15 min at 37°C before blocking and per-
meabilizing with 5% milk in phosphate-buffered saline
(PBS) containing 0.4% Triton X-100. Then the cells were
incubated overnight with anti-b-catenin antibody (Cell
Signaling Technology, Danvers, MA) at 4°C. Next, the
cells were stained with the Alexa 488 fluorophore-conju-
gated secondary antibody (Invitrogen, Carlsbad, CA) and
DAPI for 1 hr at room temperature. Immunofluorescence
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scope (Leica DM IRB) and imaged using QImaging
Retiga 4000R camera.
Flow analysis
H1650 and H1650-ER1 cells (2 × 10
5) were fixed in 1%
paraformaldehyde for 10 min at 37°C and then incubated
overnight with Alexa647-CD24 (BD Biosciences), FITC-
CD44 (BD Biosciences), APC-CD133 (Miltenyi Biotec),
PE-anti-SSEA-3 (BD Pharmingen), SSEA-4 (Santa Cruz),
Tra-1-60 (Santa Cruz), and Tra-1-80 antibodies (Santa
Cruz) (1:500 in PBS with 2% FBS and 0.1% NaN3)a t4 ° C .
After 30 min of secondary stain with Alexa 488 anti-
m o u s eI g Gs e c o n d a r ya n t i b o d y( f o rS S E A - 4s t a i n e d
cells), and PE-anti-mouse IgM antibody (for Tra-160 and
Tra-1-80), cells were analyzed on BD LSR II flow cyt-
ometer. Control samples were incubated with only sec-
ondary antibody or APC-mouse IgG and PE-rat IgM
antibodies.
Results and discussion
Characterization of an erlotinib resistant cell line
An erlotinib resistant NCI-H1650 subline (H1650-ER1)
was generated by progressively exposing the cells to
increasing concentrations of erlotinib [31]. The resistant
phenotype was characterized by quantifying cell viability at
different concentrations of erlotinib and also via a clono-
genic assay. Sequencing of the EGFR gene revealed the
persistence of the deletion mutation ΔE746-A750 within
the EGFR kinase domain in both H1650 and the resistant
H1650-ER1 subline; however, no additional mutation was
observed in the EGFR open reading frame in H1650-ER1
cells. Moreover, MET amplification, often associated with
acquired erlotinib or gefitinib resistance, was not observed.
Since cells with a mesenchymal phenotype are generally
more resistant to EGFR-TKI treatment than cells with an
epithelial phenotype, as shown in both in vitro studies and
clinical samples [16,32,33], we analyzed the gene expres-
sion profile of epithelial and mesenchymal markers in
H1650 and H1650-ER1 cells. There was a striking differ-
ence in the expression of genes associated with an epithe-
lial to mesenchymal transition (EMT). While expression of
E-cadherin and occludin were downregulated, expression
of vimentin and fibronectin were upregulated in H1650-
ER1 cells compared to parental cell line (p-value < 0.005)
( F i g u r e1 A ) .M o r e o v e r ,t h et r a n s c r i p t i o nf a c t o r sS n a i l ,
Twist, and Zeb, which are known to promote transition of
cells toward a mesenchymal phenotype, were also upregu-
lated in H1650-ER1 cells as compared to H1650 cells (p-
value < 0.05) (Figure 1B). Immunofluorescence analysis
showed that b-catenin remained localized at the mem-
branes in 68% of H1650 cells as opposed to 33% of
H1650-ER1 cells (p-value < 0.01), whereas there was
greater cytoplasmic localization of b-catenin in H1650-
ER1 cells (51% of H1650-ER1 cells vs. 18% of H1650 cells,
p-value < 0.01) (Figure 1C). In addition, resistant cells also
displayed enhanced motility (p-value < 0.05) measured as
the ability to heal a defect in a cell monolayer (Figure 1D).
However, there was no obvious change in morphological
phenotype between H1650 and H1650-ER1 cells. Taken
together our observations suggest that H1650-ER1 cells
have undergone a partial EMT.
Analysis of CSC and embryonic stem cell markers
To characterize whether H1650-ER1 cells are enriched
with a cell population possessing stem cell properties, we
analyzed the expression of CSC surface markers CD24,
CD44, and CD133 and embryonic stem cell markers
including SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81. As
demonstrated in Figure 2A, approximately twice as many
H1650-ER1 cells displayed CD44
high/CD24
low expression
patterns as compared to H1650 cells. The CD44
high/
CD24
low cells comprise a small fraction of the total
H1650-ER1 population, representing less than 2% of the
Table 1 Sequences of oligonucleotide primers used in this study
Gene Forward Reverse
E-cadherin 5’-AGGAATTCTTGCTTTGCTAATTCTG 5’-CGAAGAAACAGCAAGAGCAGC
Vimentin 5’-GAGAACTTTGCCGTTGAAGC 5’-CTAACGGTGGATGTCCTTCG
Fibronectin 5’-GTT GTT ACC GTG GGC AAC TC 5’-CTG ACG GTC CCA CTT CTC TC
Occludin 5’-TTGGGACAGAGGCTATGG 5’-ACCCACTCTTCAACATTGGG
Snail 5’-TTCCAGCAGCCCAACGACCAG 5’-CGGACTCTTGGTGCTTGTGGA
Twist 5’-GGAGTCCGCAGTCTTACGAG 5’-TCTGGAGGACCTGGTAGAGG
Oct3/4 5’-CAGTGCCCGAAACCCACAC 5’-GGAGACCCAGCAGCCTCAAA
SOX2 5’-CAAGATGCACAACTCGGAGA 5’-GTTCATGTGCGCGTAACTGT
NANOG 5’-CAGAAGGCCTCAGCACCTAC 5’-ATTGTTCCAGGTCTGGTTGC
ID2 5’-GACCCGATGAGCCTGCTATAC 5’-AATAGTGGGATGCGAGTCCAG
BMI-1 5’-GATGCCACAACCATAATAGAA 5’-TCATTCACCTCCTCCTTAGAT
STAT3 5’-GGGTGGAGAAGGACATCAGCGGTAA 5’-GCCGACAATACTTTCCGAATGC
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of several cancers including lung, brain, prostate and
pancreatic cancer [22,23,34-37]. Our study revealed that
resistant H1650-ER1 cells were substantially enriched for
CD133+, SSEA-3+, SSEA-4+, and Tra-1-60+ populations
as compared to parental H1650 cells (Figure 2B). No dif-
ferential expression between H1650 and H1650-ER1 cells
was observed for Tra-1-81.
mRNA expression levels of transcription factors OCT3/
4, NANOG, SOX-2, and inhibitor of differentiation 2
(ID2) were compared among H1650 and H1650-ER1 cells.
These genes encode proteins involved in self-renewal of
undifferentiated stem cells and all of these genes were
expressed to a greater extent in H1650-ER1 cells (p-value
< 0.05) than in the parental H1650 cells (Figure 2B).
While expression of individual stem cell markers, includ-
ing OCT4, in somatic and cancer stem cells has been
questioned [38], a role of OCT4 and NANOG expression
in regulating epithelial-mesenchymal transitions, tumor-
initiating ability, and metastasis in lung adenocarcinomas
has been reported [39]. Taken together, these experiments
indicate that the H1650-ER1 resistant subline expresses
markers that have been associated with various adult and
pluripotent stem cells at a higher level than the parental
Figure 1 Characterization of H1650-ER1 cells. (A) mRNA expression of E-cadherin, vimentin, occludin and fibronectin in H1650 and H1650-ER1
cells was measured by quantitative RT-PCR. Fold change expression was normalized with respect to H1650 cells. (B) mRNA expression of Snail,
Twist and Zeb1 in H1650 and H1650-ER1 cells was measured by quantitative RT-PCR. Fold change expression was normalized with respect to
H1650 cells. Error bars represent s.e.m. (n = 3). (C) Immunofluorescence of H1650 and H1650-ER1 cells stained with DAPI (blue) and antib-catenin
antibody (green). (D) H1650 and H1650-ER1 cells were seeded on 6 well plates. After 48 hr, a scratch was induced in the confluent cell
monolayer. Images were obtained at time t = 0 and after 12 hr (t = 12) to monitor cell migration. Percent cell migration was calculated based
on migration of H1650 cells. The error bars represent s.e.m. (n = 3).
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Page 5 of 14Figure 2 Expression of stem cell markers. (A) Analysis of CD44 and CD24 expression in H1650 and H1650-ER1 cells by flow cytometry. (B)
Flow cytometric analysis of CD133, SSEA-3, SSEA-4, Tra-1-60, and Tra-1-81 expression in H1650 and H1650-ER1 cells. Quantification of cells
staining positively for different markers. The error bars represent s.e.m. (n = 3). H1650-ER1 cells were enriched for CD133+, SSEA-3+, SSEA-4+, and
Tra-1-60+ populations as compared to parental H1650 cells (p-value < 0.05). No differential expression between H1650 and H1650-ER1 cells was
observed for Tra-1-81. (C) mRNA expression of OCT3/4, NANOG, SOX-2, and ID2 in H1650 and H1650-ER1 cells was measured by quantitative RT-
PCR. Fold change expression was normalized with respect to H1650 cells. The error bars represent s.e.m. (n = 3).
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iating H1650-ER1 phenotypes remain unclear.
Detection of tumor spheroid cells with self-renewal
capability
One critical property of stem cells is their ability to self-
renew. We evaluated the self renewal properties of H1650-
ER1 cells by the ability of individualized cells to form spher-
oids when seeded in agarose and cultured in serum free
medium supplemented with EGF and bFGF. Within 48 h,
cells formed three dimensional aggregates and eventually
generated spheroids (Figure 3A). Some cellular aggregates
of H1650 cells were observed after 48 h, but the vast major-
ity of these aggregates collapsed and disintegrated within a
few days. Few of these aggregates gave rise to spheroids
(Figure 3A). As shown in Figure 3B, the spheroid formation
frequency of H1650-ER1 (21 ± 3 spheroids/6 × 10
3 cells)
was significantly higher than that of H1650 (4 ± 1 spher-
oids/6 × 10
3 cells) cells at day 15 (p-value < 0.01). More-
over, as observed in Figure 3A, much larger spheroids were
formed by H1650-ER1 cells (170 ± 22 μm) than the paren-
tal cells (78 ± 6 μm). The clonogenicity of H1650-ER1 cells
Figure 3 H1650 and H1650-ER1 cells were cultured under non-adherent conditions in serum free medium and spheroids were
counted after 15 days. (A) Images of spheroids generated by H1650 and H1650-ER1 cells. The scale bar corresponds to 50 μm. (B)
Quantification of spheroids generated. H1650 and H1650-ER1 cells were seeded in 6 well plates at a density of 6000 cells per well. The resistant
subline generated a significantly higher number of spheroids (p-value < 0.01). Each data point represents the mean of three independent
experiments. The error bars represent s.e.m. (n = 3). (C) Clonogenicity of H1650-ER1 cells determined by limiting dilution assay. Cells were
seeded in 6 well plates at density varying from 12-6000 cells per well. Each data point represents the mean of 6 wells. The error bars represent
S.D. (n = 6). (D) Self renewal ability was determined by dissociating spheres into single cells, replating them under non adherent conditions, and
counting generation of secondary spheres after 15 days. Each data point represents the mean of 6 replicates. The error bars represent S.D. (E)
mRNA expression of OCT3/4, NANOG, BMI-1 and STAT3 in H1650-ER1, ER1 spheroids (3
rd generation) and adherent cells were measured by
quantitative RT-PCR. Fold change expression was normalized with respect to H1650-ER1 cells. The error bars represent s.e.m. (n = 3).
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revealed that ~1 in 12 cells possessed the capacity to give
rise to a spheroid (Figure 3C).
To further investigate the self renewal potential, spher-
oids from H1650-ER1 cells were dissociated into single
cells and cultured under non adherent conditions for
5 generations. Spheroids from all generations formed sec-
ondary spheroids. As shown in Figure 3D, compared to
the first generation, significantly more H1650-ER1
spheroids were observed after serially passaging in culture,
confirming the self-renewal ability of the resistant subline.
(p-value < 0.05 for 3
rd,4
th and 5
th generations).
Dissociated single cells from spheroids were also cul-
tured in adherent conditions in RPMI 1640 containing
10% FBS to induce differentiation. Expression of the genes
OCT3/4, NANOG, BMI-1 and STAT3, which are asso-
ciated with pluripotency in stem cells [40-42], was evalu-
ated by RT-PCR in H1650-ER1 cells, H1650-ER1 tumor
Figure 4 Identification and analysis of H1650 and H1650-ER1 side population (SP) cells. (A) The cells were stained with DCV dye blue-red
profile. As a control, verapamil (50 μM) was added to the cells. SP cells were gated as the population of low DCV dye containing cells that
disappeared upon verapamil treatment. A typical flow cytometry plot is shown where the SP fraction corresponds to 7% H1650 and 15% H1650-
ER1 cells. Three independent experiments were carried out (B) H1650-ER1 SP and non SP cells were sorted and cultured for 10 days, stained with
DCV dye and reanalyzed. SP cells generated SP and non SP fractions identical to H1650-ER1 cells while non SP cells generated mainly non SP
cells. A representative plot is shown here. (C) Generation of tumor spheroids by SP and non SP cells. 6000 cells were seeded per well in 6 well
plates and tumor spheroid generation was assessed by counting after 15 days. The error bars represent S.D. (n = 6).
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H1650-ER1 cells, spheroids showed greater expression of
OCT3/4, NANOG and BMI-1 (p-value < 0.05), suggesting
a more stem like character for this subgroup (Figure 3E).
However, STAT3 expression was downregulated. The
reduced expression levels of these genes in adherent cells
suggest that the cells have started to differentiate; levels of
OCT3/4 and NANOG in adherent cells were not signifi-
cantly different from H1650-ER1 cells (p-value > 0.05).
Analysis of SP phenotype
Side population (SP) cells refer to cells which are highly
enriched in stem cell activity. These cells are identified
and/or isolated on the basis of their ability to efflux
Hoechst 33342 or DyeCycle Violet (DCV) dye due to
overexpression of ABCG2, an ATP binding cassette
transporter [30]. We evaluated the existence of SPs in
H1650 and H1650-ER1 cells by staining them with DCV
dye to generate a DCV blue-red profile. As a control,
verapamil, an ABCG2 specific inhibitor, was added. The
SP gate was defined as region corresponding to cells
that exhibited low DCV dye content in the absence of
verapamil. Analysis of SPs in the parental H1650 cell
line and the erlotinib resistant H1650-ER1 subline
revealed differential SP fractions, ranging from 0.2 ±
0.01 and 4 ± 2 (with and without verapamil) for H1650
to 0.07 ± 0.05 and 15 ± 2.5 for H1650-ER1 cells (Figure
4A), suggesting EGFR-TKI exposure selectively enriched
cells with stem cell activity (p-value < 0.05).
To investigate differentiation capability, FACS-sorted SP
and non SP cells from H1650-ER1 were cultured under
the same culture conditions for 10 days, restained with
DCV dye and reanalyzed. Analysis indicates that sorted SP
cells generated 20% SP cells upon subculture, demonstrat-
ing that SP cells can differentiate to non SP cells. Sorted
non SP cells generated only 6% SP cells, which may have
generated from the residual SP cells or transition of non-
SP cells to SP cells (Figure 4B). We next evaluated the self
Figure 5 Tumorigenicity of H1650 and H1650-ER1 cells was examined in vitro b yas o f ta g a ra s s a y . Dissociated cells resuspended in
0.35% agar were plated on 5% agar and the number of colonies counted after 15 days. (A) Images showing the colonies formed by H1650 and
H1650-ER1 cells. The scale bar corresponds to 20 μm. (B) Quantification of colonies formed from 2500 cells in each well. The resistant subline
formed a significantly higher number of colonies (p-value < 0.05). The error bars represent s.e.m. (n = 3).
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tion ability. As shown in Figure 4C, SP cells gave rise to
significantly higher number of spheroids as compared to
non SP cells. These observations reveal the ability of SP
cells to undergo asymmetrical division to self renew as
well as generate differentiated tumor cells.
Evaluation of in vitro tumorigenicity
A definite hallmark of CSCs is their tumorigenic potential.
The ability of transformed cells to form colonies in soft
agar is closely related to in vivo carcinogenesis and is
often used as a surrogate in vitro assay for tumorigenicity
[43,44]. To quantify colony forming efficiency, 2500 cells
in 0.35% agar were seeded on top of 0.5% agar. The
number of colonies greater than 20 μm was counted after
2 weeks. As illustrated in Figure 5A and 5B, H1650-ER1
cells formed a significantly higher number of colonies
compared to H1650 cells, suggesting the resistant subline
is comprised of higher number of cancer stem cell-like
cells than the parental cells.
Investigating the role of cancer cells with stem cell
phenotypes in TKI resistance
Our studies revealed that H1650-ER1 cells are enriched
with cancer stem cell like cells. Next we investigated the
role of these cells in inducing resistance to erlotinib ther-
apy. Towards this aim, we determined whether SP cells
preferentially survive erlotinib exposure as compared to
Figure 6 Effect of erlotinib on cell growth. (A) Dose-response curves of parental H1650, resistant subline H1650-ER1, sorted ER1-SP and ER1-
non SP cells following incubation with varying concentrations of erlotinib for 48 hr. Each data point represents the mean of three independent
experiments. The error bars represent s.e.m. (n = 3). (B) Dose-response curves of parental H1650, sorted H1650-SP and H1650 - non SP cells
following incubation with varying concentrations of erlotinib for 48 hr. Each data point represents the mean of six replicates. The error bars
represent S.D. (n = 6). (C) Quantification of spheroid formation by 6000 H1650-ER1 cells per well under the continuous presence of erlotinib.
Each data point represents the mean of two independent experiments. The error bars represent s.e.m. (n = 3).
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Page 10 of 14Figure 7 Side population and tumor spheroid analysis of SCC-1, SCC-1-Erl-R and SCC-1-Gef-R cells. (A) Side population (SP) analysis of
SCC-1, SCC-1-Erl-R and SCC-1-Gef-R cells. (B) Quantification of spheroids generated per well. 6000 cells were seeded in each well of 6 well plates
and spheroid generation was quantified after 15 days. Resistant sublines generated a significantly higher number of spheroids (p-value < 0.05).
Each data point represents the mean of two independent experiments. The error bars represent s.e.m. (n = 3).
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Page 11 of 14non-SP cells. As shown in Figure 6A, higher viability at all
erlotinib concentrations was observed in SP cells. Erlotinib
inhibition of proliferation of non-SP cells matches that of
H1650 parental cells closely. Next, we characterized the
resistance phenotype of SP cells of H1650 parental cell
line. As illustrated in Figure 6B, SP cells exhibited greater
resistance to erlotinib insult than non SP cells, and similar
resistance as the H1650-ER1 subline.
The resistance phenotype of these stem like cells was
further confirmed by investigating spheroid forming
ability of H1650-ER1 cells under continuous exposure
to 10 μMa n d5 0μM of erlotinib (Figure 6C). The pre-
s e n c eo fe r l o t i n i bd i dn o th a v eas t r i k i n ge f f e c to n
spheroid formation frequency (17 ± 3 spheroids/6 × 10
3
cells without erlotinib, 13 ± 1 spheroids/6 × 10
3 cells
with 10 μM erlotinib, 10 ± 3 spheroids/6 × 10
3 cells
with 50 μM erlotinib, p-value > 0.05). These observa-
tions indicate that these putative cancer stem cells are
inherently resistant to erlotinib treatment.
Similar to an earlier study which demonstrated the
existence of an erlotinib resistant mesenchymal subpo-
pulation expressing CD44
high/CD24
low markers in differ-
ent erlotinib naïve NSCLC cell lines and tumors [15],
our study indicates that the lung cancer cell line H1650
consists of a population of putative cancer stem cells
which are inherently resistant to erlotinib. Prolonged
exposure of H1650 cells to erlotinib resulted in the
selection of these cancer stem like cells in the erlotinib
resistant H1650-ER1 cells, which in turn resulted in the
acquisition of resistance to erlotinib.
Detection of cancer stem-cell like cells in erlotinib
resistant head and neck cancer sublines
To exclude the possibility of occurrence of erlotinib resis-
tance in generating cell populations with cancer stem cell
properties only in H1650 cells, we investigated CSC
properties in human head and neck squamous carcinoma
cell line SCC-1 and EGFR TKI refractory sublines (SCC-
1-Erl-R and SCC-1-Gef-R) [45]. Side population analysis
revealed that the SCC-1 cell SP consisted of approxi-
mately 0.6% and 0.5% of cells in the presence and
absence of verapamil, respectively, indicating that these
cells did not contain a significant side population of stem
cell like cells (Figure 7A). However, the SCC-1-Erl-R SP
fraction contained 0.8% and 1.8% of cells and the SCC-1-
Gef-R SP contained 1.0% and 5.8% of cells in the pre-
sence and absence of verapamil, highlighting the pre-
sence of drug-effluxing side population cells within the
resistant sublines. Next, the ability of these cells to self-
renew in spheroid culture was tested. As demonstrated in
Figure 7B, when cultured under serum free non adherent
conditions, a significantly increased number of spheroids
was formed by the resistant sublines.
Collectively, our study indicates the presence of a
population of cells with CSC traits in EGFR TKI naïve
cancer cells, which are resistant to TKI therapy. So,
while TKIs can inhibit kinase activity in differentiated
cancer cells, they have little effect on putative CSCs.
Prolonged exposure to these TKIs results in selection of
cells with CSC phenotypes leading to acquisition of
resistance towards EGFR TKI therapy.
Conclusion
Our studies indicate that prolonged exposure of the
NSCLC cell line H1650 to erlotinib selects for a subpo-
pulation of erlotinib resistant cells which are enriched in
stem cell markers and possess stem cell properties in
vitro. A resistant subline, H1650-ER1, expressed
enhanced level of stem cell surface markers and also
exhibited increased mRNA expression of transcription
factors OCT3/4, NANOG, SOX-2, and ID2. H1650-ER1
cells also showed increased self renewal and the ability
to differentiate, considered fundamental properties of
CSCs. Our studies indicated that continuous exposure
of H1650 cells to erlotinib selected for cells with CSC
traits. Furthermore, these cells were found to be less
sensitive to erlotinib treatment as determined by cell
viability and tumor spheroid formation in the presence
of different concentrations of erlotinib. To ascertain that
the existence of CSC like cells in H1650 and corre-
sponding enrichment upon erlotinib treatment in
H1650-ER1 cells is not specific to H1650 cell line, pre-
sence of cells with CSC traits was also investigated in
human head and neck squamous carcinoma cell line
SCC-1 and EGFR TKI refractory sublines (SCC-1-Erl-R
and SCC-1-Gef-R). We also demonstrated the existence
of putative CSCs in SCC-1 as well as SCC-1-Erl-R and
SCC-1-Gef-R cells via side population analysis and
tumor spheroid formation assay.
In conclusion, our study provides compelling evidence
that resistance to molecular targeted therapies may be
due to cancer stem cell-like cells which are intrinsically
resistant to erlotinib treatment. These cells are present
even before erlotinib treatment. However, erlotinib
treatment selects for these cells and enrichment of cells
with CSC markers and in vitro phenotypes results in the
acquisition of resistance. The study suggests that supple-
mentation of EGFR kinase inhibition with strategies to
target cancer stem cell-like populations may increase
effectiveness of EGFR inhibition therapies.
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